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Studies in experimental models (1953-1956) demonstrated that 
acquired donor-specific allotolerance in immunologically immature 
or irradiated animals is strongly associated with donor leukocyte 
chimerism. Bone marrow transplantation in immune-deficient or 
cytoablated human recipients was a logical extension (1968). In 
contrast. clinical (1959) and then experimental organ transplanta-
tion was systematically accomplished in the apparent absence of 
leukocyte chimerism. Consequently. it was assumed for many years 
that success with organ and bone marrow transplantation involved 
fundamentally different mechanisms. With the discovery in 1992 of 
small numbers of donor leukocytes in the tissues or blood of 
long-surviving organ recipients (microchimerism). we concluded 
that organ engraftment was a form of leukocyte chimerism-
dependent partial tolerance. In this initially controversial para-
digm. alloengraftment after both kinds of transplantation is the 
product of a double immune reaction in which responses. each to 
the other. of coexisting donor and recipient immune systems 
results in variable reciprocal donal exhaustion. followed by pe-
ripheral clonal deletion. It was proposed with Rolf Zinkernagel that 
the individual alloresponses are the equivalent of the MHC-re-
stricted T cell recognition of, and host response to, intracellular 
parasites and that the mechanisms of immune responsiveness, or 
nonresponsiveness. are governed by the migration and localiza-
tion of the respective antigens. Elucidation of the mechanisms of 
nonresponsiveness (clonal exhaustion-deletion and immune igno-
rance) and their regulation removed much of the historical mys-
tique of transplantation. The insight was then applied to improve 
the timing and dosage of immunosuppression of current human 
transplant recipients. 
A !though organ transplantation has revolutionized the treat-
ment of organ-specific diseases, its success has been a scientific 
enigma. The mystique of transplantation was caused largely by the 
disorienting consensus reached 40 years ago that the donor leuko-
cyte chimerism that was known to be strongly associated with 
acquired donor-specific tolerance was not a factor in organ engraft-
ment. How this misapprehension became a dogma by 1963 and was 
not challenged for the next third of a century can be best understood 
from a historical perspective. 
The Leukocyte Chimerism Link with Tolerance 
The beginning of the modern era of transplantation usually is dated 
to the demonstration in 1943 by Medawar and Gibson that tissue 
rejection is an immune reaction (1, 2). Ten years later, two key 
observations by Billingham, Brent, and Medawar (3,4) revealed a 
vulnerability in this adaptive immune defense. First, it was possible 
to engraft splenic leukocytes or bone marrow cells in gestational 
and newborn mouse recipients who were too immunologically 
immature to reject the donor cells. Second, the recipients, who now 
had donor leukocyte chimerism, could freely accept skin from mice 
of the leukocyte donor strain, but from no other strain. The 
acquired tolerance to donor tissues clearly was associated with the 
leukocyte chimerism. 
This association was reinforced in 1955 when similar tolerance 
was produced in adult mice whose immune responsiveness was 
weakened with supralethal total body irradiation in advancc of 
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donor bone marrow cell infusion. The possibility now was obvious 
of engrafting donor hematolymphopoietic cells in irradiated recip-
ients preparatory to, or at the time of, organ transplantation (5-7). 
In addition, it was evident that bone marrow transplantation per se 
could be a potential means of treating hematologic disorders. 
Clinical bone marrow transplantation with either objective was 
forestalled, however, when it was demonstrated that the engraft-
ment of immune competent donor leukocytes caused graft versus 
host disease (GVHD) unless the donor and recipient had a good 
histocompatibility match (8-11). Because only a few human histo-
compatibility (HLA) antigens had been identified (12-14), clinical 
bone marrow transplantation was delayed for another decade. 
When HLA-matehed bone marrow recipients were finally pro-
duced in 1968 (15,16), the patients were analogous to the tolerant 
mice. 
The Split of Organ and Bone Marrow Transplantation 
By this time, thousands of human kidneys had been successfully 
transplanted as well as the first livers (17) and hearts (18) (Table I). 
None of these organ recipients had overt leukocyte chimerism. 
Consequently, it was not surprising that GVHD was not a compli-
cation in organ recipients, most of whom had HLA-mismatchcd 
grafts. Because none of the patients had been given an infusion of 
donor leukocytes, occult chimerism in the organ recipients was not 
even remotely suspected. In the absence of leukocyte chimerism, 
the possibility that organ engraftment was related to the tolerance 
of the mouse models, or to the tolerant human bone marrow 
recipient, was dismissed out of hand. Consistent with this consensus, 
human organ recipients (unlike bone marrow rccipients) depended 
on continuous immunosuppression, presumably for life (Table 2). 
Immunosuppression-Independent Organ Recipents 
After Irradiation. There were, however, perplexing exceptions to 
these starkly differcnt profiles, beginning with the first two 
successful kidney transplantations in the world (in any species). 
The epochal operations were performed in January and June 
1959, first by Joseph Murray and colleagues in Boston (6,19) and 
then by a Paris team led by Hamburger (20). The patients had 
been conditioned with sublethal doses of total body irradiation 
without leukocyte infusions. The kidney grafts, which were 
donated by fraternal (not identical) twins, functioned for 20 and 
26 years without maintenance immunosuppression. The results 
were astonishing. Years of effort with animals had not yielded 
a single example of kidney recipient survival exceeding 73 days 
with any kind of treatment or >30 days with irradiation alone 
(summarized in refs. 5-7). 
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Table 1. First successful transplantation of human allografts 
(survival> 1 year) 
Physician/ 
Organ City Date surgeon Ref. 
Kidney Boston 1/24/59 Merrill/Murray 6,19 
Liver Denver 7/23/67 Starzl 17 
Heart Cape Town, 1/2/68 Barnard 18 
South Africa 
Bone marrow Minneapolis 8/25/68 Gatti/Bach 15, 16 
Madison, WI 9/27/68 
After Pharmacologic Immunosuppression. In animals. Because of its 
exorbitant risk, total body irradiation was abandoned after it was 
demonstrated that the antileukemia drugs, 6-mercaptopurine (21) 
and its imidazole derivative, azathioprine, were immunosuppressive 
(22). Daily treatment with these purine analogues was first shown 
to modestly prolong the survival of skin allografts in rabbits (23, 24). 
Although kidney allografts in outbred (mongrel) dog recipients also 
were significantly protected by the drugs (25, 26), only =5% of the 
animals survived for as long as 100 days (27). Importantly, however, 
a small subset of the remaining 5% did not reject their allografts for 
prolonged periods when drug treatment was stopped (28-31). 
A much higher incidence of eventually drug-free survival was 
subsequently reported in canine liver recipients treated for 3-4 
months with azathioprine (32) or with a few perioperative doses of 
antilymphocyte globulin (ALG) (33). By 1965, it was evident that 
the liver could be engrafted permanently more readily than the 
kidney and other organ allografts after a limited course of immu-
nosuppression. Numerous later studies in inbred rodent models 
have confirmed this conclusion. 
In patients. Meanwhile, it had been recognized in a series of 
human kidney recipients that rejection developing under aza-
thioprine treatment was highly reversible with the addition of 
large doses of prednisone, and more importantly, that the 
reversal frequently was succeeded by variable degrees of donor-
specific nonreactivity (i.e., tolerance) (34). Daily azathioprine 
doses had been given to these patients for at least 1 week before 
as well as after transplantation, reserving the prednisone for 
treatment of rejection. Although rejection occurred in almost 
every case. the l-year survival of allografts from randomly 
HLA-matched parental, sibling, and more distantly related 
familial donors was an unprecedented 75% (35, 36). 
The surviving patients were still on immunosuppression at the 
time of first reporting in 1963 (34), but the development of 
tolerance was inferred from a rapidly declining need for treatment 
after the reversal of rejection. In fact, 9 (19.6%) of the 46 kidneys 
transplanted from familial donors over a period of 14 months 
beginning in the autumn of 1962 functioned for the next four 
decades. Importantly, seven of the nine eventually stopped all 
immunosuppression without undergoing rejection for periods rang-
ing from 4 to 40 years (37) (Fig. 1). Eight of the nine recipients are 
still alive and bear the longest surviving kidney allografts in the 
world today (38). 
Table 2. Differences of organ and bone marrow transplantation 
Feature marrow Organ Bone 
Host cytoablation No Yes* 
HLA matching Not essential Critical 
Principal complication Rejection GVHD 
Immunosuppression-free Rare Common 
Term for engraftment Acceptance Tolerance 
*Three decades later, it was realized that this therapeutic step accounted for 
all of the other major differences between the two kinds of transplantation. 
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Fig. 1. Nine (19%) of the 46 live donor kidney recipients treated at the 
University of Colorado over an 18-month period beginning in the autumn of 
1962. The filled portion of the horizontal bars depicts the time off immuno-
suppression. Note that the current serum creatinine concentration (CR) is 
normal in all but one patient. * indicates murdered; kidney allograft was 
normal at autopsy. 
Although the early results had been encouraging, two formal 
changes in management were made in December 1963 (39). First, 
the prelransplant administration of azathioprine was de-
emphasized because of immunosuppression-related infections that 
had delayed or prevented operation. In addition, large doses of 
prednisone were routinely started at the time of surgery rather than 
in response to rejection. This second modification was prompted by 
a nearly 20% rate of graft losses to nonreversible rejections. 
Moreover, the acute loss rate had approached 35% when the kidney 
donors (including cadavers) were genetically unrelated. 
The heavy prophylactic immunosuppression reduced the early 
graft losses. Inexplicably, however, no similar cluster of drug-free 
kidney recipients was ever produced again, anywhere in the world. 
Nearly 40 years later, after elucidation of the mechanisms of 
alloengraftment (see below), it was recognized that the changes in 
timing and dosage of immunosuppression probably were responsi-
ble. Recipients of the more tolerogenic liver continued to be seen 
occasionally during the intervening years, but only during periods 
when a steroid-sparing immunosuppression protocol was used, 
similar to that in the first kidney recipients (37. 40). 
Engraftment Without Immunosuppression. In 1966, it was demon-
strated in France (41) and promptly confirmed in England (42, 43) 
and elsewhere (44) that liver engraftment occurred with no treat-
ment at all in =20% of outbred pigs. Importantly, these pigs were 
shown by Caine et al. (45) to accept the skin or kidneys of the same 
donor. It was subsequently reported that such "spontaneous" liver 
engraftment occurs in every experiment in a limited number of 
rodent models (46-48). Heart (48, 49) and kidney allografts (50) 
also have been shown to self-induce engraftment without treat-
ment, albeit in a much shorter list of mouse strain combinations. 
Tissue Matching Versus Immunosuppression 
It was unequivocally established at an early time that histocompat-
ibility of the donor and recipient strains in rodent transplant models 
was an important factor in achieving organ engraftment. Such 
observations raised expectations that HLA matching would be an 
indispensable tool in the further development of human organ 
transplantation. When matching did not confer an important 
advantage except when there was perfect or ncar-perfect HLA 
compatibility (51, 52), clinical advances almost completely de-
pended on the development of more potent drugs. From 1964 
onward, the efficacy of these agents, used singly or in combination, 
was gauged largely by the extent to which acute rejection could be 
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Table 3. Empirical immunosuppression for organ 
transplantation (1962-2000) 
Treatment before 
transplantation 
Early after 
transplantation 
Azathioprine (1962-1963) Azathioprine 
ALG (1966-1968) Prednisone 
ALG 
Cyclophosphamide 
Cyclosporine 
Tacrolimus 
Mycophenolate mofetil 
Late after 
transplantation 
As needed to 
maintain stable 
graft function 
Azathioprine monotherapy before and after kidney transplantation at the 
University of Colorado in 1962-1963 (34); prednisone was added only to treat 
breakthrough rejections. ALG also was introduced as pretreatment (33). By 
the late 19605, both pretreatment and monotherapy were abandoned in 
preference for various early posttransplant combinations of the listed drugs 
(see text). 
prewnted. As new drugs emerged, they were evaluated alone in 
experimental animal studies. But for clinical use, they were folded 
into the formula of heavy multidrug therapy that had been originally 
developed with the modified use of azathioprine and prednisone 
Cfable 3). 
The better immunosuppressants were directly responsible for 
what has been called the "golden age" of organ transplantation. The 
additional drugs that ultimately had the greatest impact were the 
antilymphoid antibody preparations [exemplified by ALG (33), 
cyclosporine (53), and tacrolimus (54)]. The outlook for all kinds of 
organ recipients was improved, but the stepwise increase in patient 
and graft survival was most conclusively demonstrated with trans-
plantation of the nonrenal organs. For example, the I-year and 
subsequent survival of liver recipients abruptly doubled when 
cyclosporine replaced azathioprine as the baseline drug in 1980 and 
improved significantly again with the advent of tacrolimus (55) 
(Fig. 2). 
The Question of Chimerism 
By the early 1990s, the possibility that donor leukocyte chimerism 
was involved in organ engraftment had not been raised in the basic 
or clinical science literature for more than a third of a century. Tn 
the ostensible absence of chimerism, even the highly reproducible 
drug-free state observed in experimental organ transplant models 
(with or without the aid of immunosuppression) was considered to 
be something other than tolerance. Qualifying terms included graft 
acceptance. pseudotolerance, and operational tolerance. Theoret-
ical mechanisms that assigned no role to chimerism were proposed 
to explain alloengraftment. These involved suppressor, veto, or T 
regulatory cells; self-pcrpetuating cytokine profiles; idiotypic anti-
bodies; secretion by the graft of tolerizing soluble HLA antigens; 
and dcviant antigen presentation. Most of these hypotheses still 
have defenders (56, 57). 
Organ Chimerism. In retrospect, the dismissal of leukocyte chimer-
ism-associated mechanisms is surprising in view of the early rec-
ognition that implanted organ allografts promptly become mixtures 
of donor and recipient cells (i.e., organ chimerism). This was first 
demonstrated in 1968 with karyotyping studies of livers that had 
been transplanted to female recipients from male cadaveric donors 
(58). Whereas the rest of the allograft remained male. the bone 
marrow-derived passenger leukocytes including Kupffer cells were 
largely replaced with recipient female cells within 100 days. 
This transformation was widely considered to be a unique feature 
of the transplanted liver until it was shown in 1991 that most of the 
lymphoid tissues of the engrafted rat (59) and human intestine (60) 
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Fig. 2. Patient survival. The three eras of orthotopic liver transplantation at 
the universities of Colorado (1963-1980) and Pittsburgh (1981-1993), defined 
by azathioprine (AZA)-, cyclosporine (CYA)-, and tacrolimus (TACl-based im-
mune suppression. Stepwise improvements associated with the advent of 
these drugs also were made with other kinds of organs. 
were replaced by recipient cells of the same lineages. When 
analogous findings were demonstrated in successfully transplanted 
human kidney (61, 62) and thoracic organ allografts (62), it was 
obvious that all engrafted organs were chimeric structures. 
Recipient Chimerism. Circumstantial evidence. However, what had 
become of the donor leukocytes that had been replaced by recipient 
cells? There were long neglected clues. In 1962-1963, skin tests for 
tuberculin, and a panel of other intradermal antigens were per-
formed in the first kidney recipients at the University of Colorado 
and in their volunteer live donors. Recipients with negative skin 
tests developed positive tests at a 77% rate when the patients were 
given kidneys from skin test-positive donors. The results were 
explained " ... by the adoptive transfer of donor cellular immunity 
by leukocytes in the renal graft vasculature and hilar lymphoid 
tissue" (63). This explanation was generally discounted because 
neither the large quantity of passenger leukocytes nor the fact that 
these cells migrated were appreciated at the time. 
Further evidence of adoptive immunity was obtained in 1969 
with the demonstration that human liver and kidney recipients 
acquired new Ig (Gm) types of donor specificity (58, 64). And in 
1984, it was observed that anti-red cell isoagglutinins of apparently 
donor origin were responsible for the hemolysis seen in recipients 
of ABO blood group-compatible but not identical livers (65).t By 
this time (67), and in the succeeding decade (68, 69), it was shown 
that leukocyte migration is a striking phenomenon after the trans-
plantation of all organs. However, the circulating donor cells rapidly 
diminished and were undetectable with flow cytometry after 30-60 
days (60, 70, 71). Consequently, the conviction of most observers 
was that the donor cells had undergone immune elimination. 
Direct evidence. In the spring of 1992. the decisive step was taken of 
searching for donor leukocytes in the blood and tissues of 30 human 
recipients of livers or kidneys who had undergone successful 
transplantation 3-29 years previously. With sensitive cytostaining 
and PCR techniques, small numbers of donor leukocytes (micro-
chimerism) were identified in one or more peripheral recipient 
locations in all 30 patients (61, 72-74). The X or Y chromosome 
(when the donors and recipients were of the opposite sex), or 
donor-specific HLA antigens, were used as markers. At any given 
site, the donor leukocytes usually were present in larger numbers in 
liver recipients than in kidney recipients. The long-term persistence 
of multilineage microchimerism implied [as was later proved (75-
'In a more recent example of adoptive transfer, the liver was transplanted from a cadaver 
whose death had been caused by a fatal allergic reaction to peanuts. Some months later, 
the otherwise well reCipient reported potentially life-threatening symptoms after peanut 
consumption. The problem was resolved with peanut abstinence (66). 
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Fig. 3. Old (A and B) and new (C and D) views of transplantation recipients. (A) The early conceptualization of immune mechanisms in organ transplantation 
in terms of a unidirectional host versus graft (HVG) response. Although this readily explained organ rejection, it limited possible explanations of organ 
engraftment. (B) Mirror image of A, depicting the early understanding of successful bone marrow transplantation as a complete replacement of the recipient 
immune system by that of the donor, with the potential complication of an unopposed lethal unidirectional GVH response, i.e., rejection of the recipient by the 
graft. (C) Our current view of bidirectional and reciprocally modulating immune responses of coexisting immune competent cell populations. Because of variable 
reCiprocal induction of deletional tolerance, organ engraftment was feasible despite a usually dominant HVG reaction. The bone silhouette in the graft 
represents passenger leukocytes of bone marrow origin. (D) Our currently conceived mirror image of C after successful bone marrow transplantation. Recipients' 
cytoablation has caused a reversal of the size proportions of the donor and reCipient populations of immune cells. 
77)] that hematolymphopoietic precursor and stem cells are part of 
the passenger leukocyte population of organ grafts. 
A Unified View of Transplantation 
Historically, the events set in motion by transplantation had been 
defined largely in the framework of a single immunocyte popula-
tion. In the organ recipient (Fig. 3A), the subsidence of rejection 
with resulting engraftment had been ascribed to mechanisms that 
excluded a role of persisting donor leukocytes. Conversely, the ideal 
result of bone marrow transplantation had been envisioned as the 
total replacement of the recipient hematolymphopoietic cells (Fig. 
3B). A flaw in this doctrine was exposed in 1989 by the puzzling 
observation of Przepiorka et at. (78) in Seattle that essentially all 
bone marrow recipients actually had a small residual population of 
their own hematolymphopoietic cells (Fig. 3D). With the discovery 
of donor cells in long-surviving organ recipients, it was evident that 
organ engraftment (Fig. 3C) and bone marrow cell engraftment 
(Fig. 3D) were mirror-image versions of leukocyte chimerism. 
We then proposed that the seminal mechanism of both kinds of 
engraftment consisted of " ... responses of coexisting donor and 
recipient cells, each to the other, causing reciprocal clonal exhaus-
tion, followed by peripheral clonal deletion" (72) (Fig. 4). Exhaus-
tion and deletion of the dominant response of organ transplantation 
(the upright curve in Fig. 4) explained the rejection reversal and 
evolution of variable tolerance that had been first recognized 30 
years earlier in kidney recipients (34). Irradiation of the bone 
marrow recipient simply transferred immune dominance to the 
graft (the inverted response curve in Fig. 4). If both response arms 
were intact and equally immunosuppressed (as was the standard 
treatment of organ recipients), the reciprocal tolerance induction 
was the reason HLA matching was not essential for organ trans-
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plantation (79) (Fig. 5). This "nullification" effect of mutual 
tolerance induction also explained why GVHD was rarely seen after 
organ transplantation, even of lymphoid-rich allografts such as the 
intestine and liver (61, 72). 
In addition, the reason was apparent for the strong association 
between leukocyte chimerism and transplantation tolerance. 
The leukocyte was the only source of transplant antigen capable 
of migrating to host lymphoid organs and inducing the clonal 
activation on which the derivative events of exhaustion and 
deletion depended (72). Finally, immunosuppression was re-
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Fig. 4. Contemporaneous HVG (upright curves) and GVH (inverted curves) 
responses after organ transplantation. If some degree of reciprocal clonal 
exhaustion is not induced and maintained (usually requiring protective im-
mune suppression), one cell population will destroy the other. In contrast to 
the usually dominant HVG reaction of organ transplantation (shown here), 
the GVH reaction usually is dominant in the cytoablated bone marrow recip-
ient. Therapeutic failure with either type of transplantation implies the 
inability to control one, the other, or both of the responses. 
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Fig. 5. The reciprocal tolerance induction of the two immune competent cell 
populations during the first 60 days of passenger leukocyte migration that 
explains the nonessential role of HLA matching in organ transplantation. 
Cytoablation of the human bone marrow recipient (e.g., with supra lethal 
irradiation) removes the host arm of the immune interaction, leaving the 
patient dependent on HLA matching for avoidance of GVHD. The nullification 
effect of the coexisting donor and recipient cells also explains why Iymphoid-
rich organs seldom cause GVHD. 
quired for engraftment under most organ transplantation cir-
cumstances (0 prevent destruction of the inducing donor leuko-
cytes by the dominant recipient response before deletion could 
occur (61, 72). 
Immune Regulation 
This unified view of transplantation (61, 80) was considered in the 
larger context of basic immunology in two reviews with Rolf 
Zinkernagel whose earlier studies had delineated the MHC-
restricted T cell recognition of, and response to, noncytopathic 
microorganisms (i.e., intracellular parasites) (81). Zinkernagel and 
colleagues' more recent research had been focused on the role of 
small numbers of residual pathogens in maintaining immunity, or 
alternatively tolerance, to these infectious agents (82-85). The 
emphasis in our first review (86) was on the analogies between the 
adaptive immune response induced by pathogens and the response 
induced by migratory leukocytes. 
We proposed that immune responsiveness or nonresponsive-
ness to both kinds of antigen is governed by the migration and 
localization of the antigen. In this view of immune regulation, 
only two mechanisms were needed to explain alloengraftment 
(86). The first was the clonal exhaustion-deletion induced by 
migration of antigen (i,e., donor leukocytes) to host lymphoid 
organs. The second mechanism was immune ignorance. This 
applied to antigen whose presence was not recognized if it failed 
to reach a lymphoid destination (87-90). Successful transplan-
tation involved both mechanisms. 
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Fig. 6. The routes taken by passenger leukocytes of transplanted organs and 
infused donor bone marrow cells. The migration is selective at first to host 
lymphoid organs, but after 15-60 days, surviving leukocytes move secondarily 
to nonlymphoid sites. With establishment of reverse traffic (non lymphoid to 
lymphoid locations), the exhaustion-deletion induced at the outset can be 
ma i nta i ned (see text). 
The migration of donor leukocytes from an organ graft into 
the recipient is along the same hematogenous routes as those of 
a spreading non cytopathic pathogen, selectively at first to host 
lymphoid organs (67-71) (Fig. 6). After a few days or weeks, 
donor cells that escape destruction by the resulting immune 
response move onto nonlymphoid niches that are relatively 
inaccessible to cellular and humoral effector mechanisms (91, 
92) (Fig. 6, outer circle). In these privileged nonlymphoid 
locations, the passenger leukocytes could be ignored or forgot-
ten, a survival advantage analogous to that of residual micro-
organisms after a systemic infection (86, 93). The donor leuko-
cytes could migrate retrograde from these protected sites to the 
host lymphoid organs and sustain the clonal exhaustion-deletion 
induced at the outset (Fig. 6). The resulting variable transplan-
tation tolerance was analogous to the different outcomes that 
may develop after an infection such as hepatitis (86). 
Much of the historical mystique of transplantation was removed 
with this paradigm. For example, immunosuppression was not 
needed in the enigmatic pig and rodent models of organ-induced 
spontaneous tolerance because the antigraft response was too weak 
to eliminate the donor cells (Fig. 7A). The liver was the organ most 
capable of inducing tolerance because of its large content of 
passenger leukocytes. Moreover, it could be understood why the 
natural tolerance in such models can be abrogated by administering 
immunosuppression (94). 
Tolerogenic Immunosuppression 
How the new insight could be used to improve the treatment of 
future transplant recipients was examined in the second review with 
Zinkernagel in 2001 (93). We pointed out that the heavy multidrug 
immunosuppression given in most centers from the time of trans-
plantation could systematically erode the seminal tolerance mech-
anism of clonal exhaustion-deletion. To the extent this occurred, the 
recipient would be committed to unnecessarily high long-term 
immunosuppression to prevent emergence of the suboptimally 
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Fig. 7. The role of immunosuppression in deletional tolerance. (A) Spontaneous tolerance (thin line) rather than rejection (thick arrow) may develop in the 
absence of immunosuppression if the unmodified recipient response is too weak to eliminate the migratory donor cells. (8) The pretreatment principle. Recipient 
immune responsiveness is reduced into the deletable range by cytoablation or cytoreduction before arrival of the alloantigen. (e) The minimal immunosup-
pression principle. The recipient response is kept in the deletable range with immunosuppression (black bar) after transplantation. (D) The antitolerogenic effect 
of overimmunosuppression (multilayered bars) after arrival of the allograft, with variable prevention of clonal exhaustion-deletion (see text). Horizontal axis, 
time. Tx, transplantation 
deleted clone (Fig. 7D). Our first proposal was to avoid this 
self-defeating effect of treatment by administering posttransplant 
immunosuppression as sparingly as possible. 
The principle of minimalistic immunosuppression has heen dem-
onstrated in many inbred rodent models in which organ engraft-
ment follows a short course of postoperative therapy throughout 
which the antidonor response is kept in the deletable range (Fig. 
7C). However, the highly standardized treatment formulas used in 
these experimental models cannot be applied in the outbred human 
population where the immune barrier is unpredictable in any given 
case. Finding just the right amount of posttransplant immunosup-
pression can be made easier by treatment before transplantation 
(the pretreatment principle) (Fig. 7B). With the reduction of overall 
recipient responsiveness accomplished by pretreatment, the antic-
ipated (and predictably reduced) donor-specific immune response 
is more readily exhausted. The practical advantage is that the 
recipients can more safely begin their posttransplant course on 
diminished immunosuppression, followed by day-to-day decreases 
or increases as dictated by clinical events. 
In retrospect, Murray and coworkers (19) and Hamburger et al. 
(20) achieved enduring tolerance in their irradiated fraternal twin 
kidney recipients of January and June 1959 with pretreatment only 
(Fig. 7B). It was soon learned that pretreatment alone was rarely 
enough. Also in hindsight, the combination of pretreatment and 
minimum posttransplant immunosuppression had been used in the 
ultimately drug-free cluster of kidney recipients produced in Den-
ver in 1962-1963 (Fig. 8) (34). With the subsequent change to 
prophylactic immunosuppression and deemphasis of pretreatment 
that occurred worldwide, tolerant kidney recipients were no longer 
seen (Fig. 7D). Further examples of immunosuppression indepen-
dence were limited thereafter almost exclusively to a few recipients 
of the more tolerogenic liver. 
Even if the tolerogenic principles of recipient pretreatment and 
minimal posttransplant immunosuppression had been understood 
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in the 1960s and 1970s, they could not have been efficiently applied 
with the suboptimal drugs then available. Armed with modern 
drugs in 2001, pretreatment has been provided with a single large 
dose of potent antilymphoid preparations: a potent ALG (thymo-
globulinR) or a humanized mAb, alemtuzamab (campathR). Treat-
ment after transplantation was provided with conservative daily 
mono therapy (usually tacrolimus), adding other agents only in the 
event of breakthrough rejection (95, 96) (Fig. 8). When rejection 
occurred, it was treated with additional immunosuppression for as 
brief a period as possible (Fig. 8). 
Other agent 
Tacrolimu5 
Tx: 
• 
• 
• 
•• Rejection 
• 
• 
• 
• 
• 
Time 
Fig.8. Principles oftolerogenic immunosuppression (Fig. 7 8 and C) that can 
be jOintly applied under most circumstances of clinical transplantation to 
convert rejection (thick dashed arrow) to a response that can be exhausted 
and deleted. 
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Fig. 9. Course of a cadaver kidney recipient in July 2001, after pretreatment 
with 5 mg/kg ALG. Biopsy-proven rejection in the third week was treated with 
infusions of 1.0 and 0.5 g of prednisone. Daily tacrolimus (Tac.) (fully shaded 
area) was begun on the day after operation and spaced to every other day or 
longer intervals after 6'h months. 0 indicates trough levels of tacrolimus. 
Treatment has been with one dose per week for almost 2 years. 
In the cadaver kidney recipient whose course is depicted in Fig. 
9, an early rejection was reversed with two doses of prednisone. 
Weaning from tacrolimus was begun at 6 liz months by spacing 
doses to every other day and progressively longer intervals. The 
patient has been stable on one dose per week of tacrolimus since 
July 2002. The strategy, which has become our current standard of 
care, has been used for >600 kidney, liver, intestine, pancreas, or 
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